What do systematic reviews say?

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in death compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.09 [0.96, 1.24]
  2010 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 2.54 [1.56, 4.12]
  15 studies · 1666 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 910 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal may leads to lower graft loss compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.85 [0.74, 0.98]
  16 studies · 2090 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal may leads to lower adverse events: hypertension compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.82 [0.71, 0.95]
  950 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.87 [0.52, 1.45]
  7 studies · 608 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.1 [0.93, 1.3]
  6 studies · 1079 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.99 [0.69, 1.4]
  23 studies · 5427 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.43 [1.15, 1.78]
  30 studies · 5903 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.94 [0.75, 1.19]
  25 studies · 5446 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.86 [0.64, 1.15]
  7 studies · 2207 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to lower adverse events: CMV Infection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.6 [0.44, 0.82]
  13 studies · 2503 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.69 [0.47, 1]
  14 studies · 3699 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: lymphocele compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.45 [0.95, 2.21]
  8 studies · 1926 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 3.21 [1.59, 6.48]
  12 studies · 1428 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 668 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal probably leads to lower graft loss: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.72, 0.97]
  13 studies · 1831 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.9 [1.44, 2.51]
  17 studies · 3636 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 2679 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.92 [0.65, 1.3]
  17 studies · 4026 participants
  Moderate